Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Heikki Jouttijärvi, former vice president of technical operations at Menlo Therapeutics, has been named vice president of manufacturing at Adverum Biotechnologies.
Kevin Ballinger has taken the helm at Aldevron, where he will now serve as CEO. Ballinger was the former executive vice president and global president of interventional cardiology at Boston Scientific.
Wolfgang Meder has been appointed to the role of vice president of regulatory affairs and quality management at AM-Pharma. Meder was most recently the head of regulatory affairs at Correvio Pharma.
Former senior director of biostatistics at Bristol-Myers Squibb, Zhinuan Yu, has been named corporate vice president of biometrics and regulatory enabling functions at Antengene.
Nicholas Green has been named president and CEO of Avid Bioservices. Green was previously president and CEO of Therapure Biopharma.
AVM Biotechnology has hired Janet Rea, former senior vice president of regulatory, quality and clinical affairs at Atossa Therapeutics, as the company’s chief operating officer.
Kim Raineri has been named chief manufacturing and technology officer of Avrobio. Most recently, Raineri was the vice president of operations for Nikon CeLL innovation.
CADTH has appointed Suzanne McGurn to the role of president and CEO. McGurn was recently the assistant deputy minister of institutional services at the Ontario Ministry of the Solicitor General.
Chris Morabito will now serve as chief medical officer at Cardurion Pharmaceuticals. Morabito was previously at Takeda Pharmaceuticals, where he served as senior vice president and head of R&D of plasma-derived therapies.
John Friend, former chief medical officer of DRGT, was named chief medical officer at Cellectar Biosciences.
David Slack, current board member of CEND Therapeutics and former chief business officer of Viracta Therapeutics, will now serve as president and CEO of CEND.
Genomics company Cergentis appointed Joris Schuurmans to lead the company as its newest CEO. Schuurmans was most recently program manager of SkylineDx’s melanoma program.
Current Health has found its new chief medical officer in Adam Wolfberg, former chief medical officer of Ovia Health.
Cyteir Therapeutics has appointed Paul Secrist, former senior vice president of Discovery Research at Lifemine Therapeutics, to the role of chief scientific officer. Andrew Gengos was also appointed by the company to the role of chief business officer. Previously, Gengos was chief business officer and chief financial officer at AOBiome Therapeutics. Cyteir named Judson Englert, former senior director of Translational Sciences at UPMC Enterprises, to vice president of clinical research and development.
Swedish biotech Cyxone has hired Maarten Kraan to the role of senior scientific advisor. Kraan previously served as head of R&D at Pierre Fabre Pharmaceuticals.
Abby Bronson has been appointed to vice president of patient advocacy and external innovation at Edgewise Therapeutics. Prior to this role, Bronson was senior vice president of research strategy at PPMD.
Peter Hanson, who most recently held the position of chief development operations officer at Centrexion Therapeutics, has been named chief operating officer of eGenesis.
European Medicines Agency (EMA)
Emer Cooke was nominated by the EMA Management Board as the organization’s new executive director.
Evidation Health has named Sam Marwaha, who recently served as senior partner at Boston Consulting Group, to the role of chief commercial officer.
Mary Gunn has been named chief operating officer of women’s health CRO Health Decisions. Gunn was recently the vice president of general management and business development at ICON.
Humanigen has appointed Dale Chappell, founder of Black Horse Capital, to the role of chief scientific officer, David Tousley to the position of chief accounting officer, and Omar Ahmed to senior vice president. Tousley previously served as executive vice president and chief financial officer and president and chief operating officer at Sanofi Pasteur. Ahmed also served as global marketing leader of immunology at Janssen.
Tom Shea has joined ImmunoMolecular Therapeutics as its newest chief financial officer and chief operating officer. Shea was recently chief financial officer of ImmusanT. Sarah Bird, former director of clinical development at ImmunoMolecular, was promoted by the company to the role of vice president of clinical development.
Gene Kim has been hired by INOVIO to assume the role of president of INOVIO Asia. Kim was most recently chief financial officer of VGX Pharmaceuticals. Additionally, Mammen (Anza) Mammen was named INOVIO’s senior vice president of clinical development. Mammen was previously the chief of the Pandemic Warning Team for the U.S. Department of Defense (DoD).
IntroSpect Digital Therapeutics
David Keene has been named president and CEO of IntroSpect Digital Therapeutics, a new platform launched by biotech company ATAI Life Sciences. Prior to this new role, Keene was chief technology officer of Dthera Sciences.
JanOne named Doug Flanagan the company’s chief formulation advisor. Flanagan was emeritus professor at the University of Iowa College of Pharmacy.
Herma Renkema has been appointed to the position of chief early development officer of Khondrion. Previously, Renkema served as a scientist at the company.
Richard Williams has been named chief medical officer of Kinnate Biopharma. Recently, Williams was chief medical officer and global head of oncology programs at WuXi NextCODE.
Jennifer Nicholson will now serve as vice president of regulatory affairs at Kronos Bio. Prior to this appointment, Nicholson was head of global regulatory science at Acerta Pharma.
Lava Therapeutics has named Benjamin Winograd as its newest chief medical officer. Winograd most recently served as the clinical research and development therapeutic area head for multiple myeloma at Celgene.
Monica Shaw has taken the position of executive vice president, region Europe+, at LEO Pharma. Shaw recently served as vice president commercial and head of Asia Pacific region at GSK/ViiV Healthcare in Singapore. LEO also named Nathalie Joannes to the role of executive vice president of legal and compliance and general counsel. Joannes comes to Leo from Roquette Freres, where she served as group general counsel.
Steve Colletti, senior vice president of research at Lodo, has been promoted to the role of chief scientific officer. Lodo’s scientific co-founder, Brad Hover, has also been promoted to vice president of discovery research and platform technology.
Robert Richard has been appointed to the role of senior vice president of research and development at Lyra Therapeutics. Before this role, Richard led the global R&D organization at Anika Therapeutics.
Mark Fleiner, a former business group director for Spectris, has been named president of Malvern Panalytical.
Mateon Therapeutics has appointed Anthony Maida to the role of chief clinical officer of translational medicine.
Robert Jordan has been appointed to the role of vice president of research and development at Meissa Vaccines. Previously, Jordan was director of virology at Vir Biotechnology.
John Lewicki has been named chief scientific officer of Mereo BioPharma. Before this role, Lewicki was president and CEO of OncoMed Pharmaceuticals. Ann Kapoun is another new hire at Mereo, where she will now serve as senior vice president of translational research and development. Kapoun was most recently senior vice president of R&D at ESCAPE Bio.
Ben Machielse has been named executive vice president of chemistry, manufacturing and controls at Novavax. Machielse currently serves on the board of several pharmaceutical companies, including Polyneuron Pharmaceuticals and Comet Therapeutics.
Gwenn Hansen has been promoted from senior vice president of research to the role of chief scientific officer at Nurix Therapeutics. The company has also hired Michael Lotze, former chief scientific officer of Iovance Biotherapeutics, as its chief cellular therapy officer. Robert Brown, former clinical team lead at Allogene Therapeutics, has also joined Nurix as its vice president of clinical development.
Marty Duvall, former CEO of Tocagen, has been named CEO of Oncopeptides. Jakob Lindberg, Oncopeptides outgoing CEO, has assumed the position of chief scientific officer at the company.
Colin Meyer, chief medical officer at Reata Pharmaceuticals, has been promoted to the role of chief research and development officer and executive vice president. Seemi Khan, former development team lead at Mitsubishi Tanabe Pharma America, has been hired to assume the position of chief medical officer at Reata. Additionally, Reata has hired Andrea Loewen to the role of vice president of global regulatory affairs. Loewen was most recently vice president and head of regulatory affairs at Retrophin. Kevin Johnston has also joined Reata as its vice president and chief technical officer. Johnston recently served as vice president of supply chain and logistics at Tesaro.
Fatih Uckun, who previously served as head of immuno-oncology at Ares Pharmaceuticals, has been named chief medical officer and chief scientific officer of Reven Holdings.
Gilbert Wagener has been named senior vice president and chief medical officer of Rexgenero. Wagener was tapped from Sensorion, where he served as interim chief medical officer.
Oscar Izeboud was appointed to lead Scenic Biotech as its new CEO. Previously, Izeboud served as managing director at NIBC Bank N.V.
Thomas Garite has been tapped by Sera Prognostics to assume the role of vice president of clinical sciences. Most recently, Garite was director of research and education at Obstetrix.
Seres Therapeutics has appointed Terri Young, former vice president of global commercial strategy at Sage Therapeutics, to the roles of executive vice president and chief commercial and strategy officer.
Richard Sachse has been appointed to the role of chief medical officer at SOTIO. Prior to joining SOTIO, Sachse was chief scientific officer at Neovii Pharmaceuticals.
Storm Therapeutics has appointed Josefin-Beate Holz to the role of chief medical officer. Holz was recently chief medical officer of Calypso Biotech.
John Johnson has been named CEO of Strongbridge Biopharma. Currently, Johnson is director of Verastem Oncology.